IPMN Surveillance
On this page
Direct answer
Main duct or branch duct: that single distinction decides surgery versus surveillance in intraductal papillary mucinous neoplasm. Main-duct IPMN is pre-malignant terrain and is generally resected in fit patients; branch-duct IPMN is stratified by the Fukuoka framework — "high-risk stigmata" go to surgery, "worrisome features" earn an EUS, and featureless cysts watch with MRI at lengthening intervals. The system exists because these mucin-producing lesions shade into pancreatic cancer, and the exam expects the thresholds verbatim.
What you must remember
- Types: main-duct IPMN (diffuse or segmental pancreatic duct dilatation, often pancreatitis-like presentations), branch-duct IPMN (grape-like microcystic cluster, usually incidental on CT), and the mixed type.
- High-risk stigmata (resect): obstructive jaundice with a cystic head lesion; enhancing mural nodule ≥5 mm; main pancreatic duct ≥10 mm.
- Worrisome features: cyst ≥3 cm; thickened or enhancing cyst walls; non-enhancing mural nodule; duct 5–9 mm; abrupt duct calibre change with distal atrophy; lymphadenopathy; rising CA 19-9; new or worsening diabetes; interval growth of about 2.5 mm/year or more (IAP 2017).
- The EUS fork: a worrisome cyst undergoes EUS — an enhancing nodule ≥5 mm or main-duct features push to resection; lesser findings justify either surgery or intensified surveillance depending on fitness and surgical risk.
- Surveillance rhythm: featureless branch-duct cysts get MRI/CT at 1 year, then roughly every 2 years; intervals lengthen with stability; cyst fluid CEA >192 ng/mL supports a mucinous lesion.
- Stop rules: surveillance ends when life expectancy falls below about 5 years or comorbidity forbids surgery — over-investigating the elderly is itself an exam-marked error.
- Main-duct exception: in elderly or unfit patients with modest duct dilatation, surveillance instead of surgery is accepted — absolutism loses marks.
- History anchors: new-onset diabetes, unexplained acute pancreatitis, and jaundice in a cyst-carrier convert the next scan into a resection discussion.
The five-millimetre nodule
The perspective worth internalising: IPMN management is threshold practice, and the thresholds are quoted as numbers because half-measures fail. A mural nodule under 5 mm may be mucin globule rather than tumour; above 5 mm with enhancement it is presumed epithelium worth resecting — which is why EUS enhancement, not CT suspicion, settles the argument. The second trap is the main-duct reflex: candidates learn "main duct = surgery" and apply it to the 84-year-old with 11 mm of duct and ischaemic heart disease; guidelines explicitly allow surveillance in the unfit, and the exam marks the judgement. Third, surveillance has an expiry: chasing a 2 cm stable cyst annually in a patient of 82 with no surgical future is over-investigation, and the stop rule (life expectancy under about 5 years) is a guideline line like any other. Finally, cyst fluid CEA above 192 ng/mL as the mucinous marker — the small fact that separates the prepared candidate from the pattern-matcher.
Frequently asked questions
What are the Fukuoka high-risk stigmata mandating resection?
Obstructive jaundice with a cystic head lesion, an enhancing mural nodule of 5 mm or more, and main pancreatic duct dilatation of 10 mm or more.
Which cysts undergo EUS rather than immediate surgery?
Branch-duct IPMNs with worrisome features — cyst ≥3 cm, thickened walls, non-enhancing nodule, duct 5–9 mm, growth, or new diabetes — after which EUS findings decide.
What cyst fluid marker supports a mucinous (IPMN) lesion?
Cyst fluid CEA above 192 ng/mL — the standard cut-off distinguishing mucinous from non-mucinous cysts.
How is a featureless branch-duct IPMN followed?
MRI or CT at 1 year, then approximately every 2 years, lengthening intervals with stability — and stopping when life expectancy is under about 5 years.
Can main-duct IPMN ever be surveilled?
Yes — in elderly or unfit patients with modest duct dilatation, surveillance is accepted instead of high-risk surgery.